逍遥散在治疗心脏神经官能症中的疗效观察

目的:观察逍遥散在治疗心脏神经官能症中的疗效。方法:选取2012年5月至2015年5月在我院确诊为心脏神经官能症的门诊患者60例采用随机数字表法分为治疗组和对照组各30例,对照组使用乌灵胶囊、谷维素治疗,治疗组在对照组的基础上加用逍遥散治疗,并对治疗前后进行汉密尔顿抑郁量表(HAMD)、焦虑量表(HAMA)评分。结果:治疗组总有效率93.3%,对照组总有效率76.7%,两组总有效率比较提示治疗组疗效优于对照组(P0.05)。联合治疗组治疗后的HAMA评分为(10.34±5.88),对照组HAMA评分为(15.97±6.43),治疗组焦虑改善情况优于对照组(P0.05),联合治疗组治疗后的抑郁(HAMD)评分为(35.55±7.36),对照组的抑郁(HAMD)评分为(58.97±4.24),治疗组焦虑改善情况优于对照组(P0.05)。结论:逍遥散在治疗心脏神经官能症中有显著疗效。     

稳心颗粒联用倍他乐克治疗冠心病并室性早搏疗效观察

目的 观察稳心颗粒用倍他乐克治疗冠心病并室性早搏临床疗效.方法 选择129例确诊为冠心病并室性早搏患者,随机分为3组.联合治疗组(43例):口服稳心颗粒和倍他乐克片,稳心颗粒组(43例):口服稳心颗粒,倍他乐克组(43例):倍他乐克片口服.3组治疗时间为4周,分别观察治疗前后动态心电图和临床症状的变化.结果 联合用药组显效率69.8%,有效率25.6%,总有效率95.3%,心电图有效率93%;稳心颗粒组显效率37.2%,有效率30.2%,总有效率67.4%,心电图有效率79%;倍他乐克组显效率32.5%,有效率37.2%.总有效率69.8%.心电图有效率79%.经统计学处理,3组中联合用药组显效率、总有效率、心电图有效率与稳心颗粒组和倍他乐克组比较差异有统计学意义(P＜ 0.05).结论 稳心颗粒联用倍他乐克治疗冠心病并室性早搏的效果比单用稳心颗粒和倍他乐克明显增高,临床症状明显改善.     

步长稳心颗粒治疗心脏神经官能症60例疗效观察

目的 观察步长稳心颗粒治疗心脏神经官能症的临床疗效。方法将120例患者随机分为治疗组和对照组各60例，对照组采用常规疗法，治疗组采用步长稳心颗粒治疗，15天为1个疗程。结果治疗组临床症状改善效果明显优于对照组，且复发率极低。结论步长稳心颗粒治疗心脏神经官能症明显优于常规疗法。     

稳心颗粒联用倍他乐克治疗扩张型心肌病并室性早搏疗效观察

目的：观察稳心颗粒用倍他乐克治疗扩张型心肌病并室性早搏临床疗效。方法：选择129例确诊为扩张型心肌病并室性早搏患者,随机分为3组。联合治疗组（43例）：口服稳心颗粒和倍他乐克片;稳心颗粒组（43例）：口服稳心颗粒;倍他乐克组（43例）：倍他乐克片口服。3组治疗时间为4周,分别观察治疗前后动态心电图和临床症状的变化。结果：联合用药组显效率69.8%,有效率25.6%,总有效率95.3%,心电图有效率93%;稳心颗粒组显效率37.2%,有效率30.2%,总有效率67.4%,心电图有效率79%;倍他乐克组显效率32.5%,有效率37.2%,总有效率69.8%,心电图有效率79%。经统计学处理,3组中联合用药组显效率、总有效率、心电图有效率与稳心颗粒组和倍他乐克组比较差异有统计学意义（P〈0.05）。结论：稳心颗粒联用倍他乐克治疗扩张型心肌病并室性早搏的效果比单用稳心颗粒和倍他乐克明显增高,临床症状明显改善。     

稳心颗粒治疗慢性心力衰竭患者焦虑抑郁症状的疗效观察

目的观察稳心颗粒对慢性心力衰竭患者焦虑、抑郁症状治疗的有效性,以及对慢性心力衰竭合并心律失常的治疗效果。方法选取2010年9月至2012年1月在河北大学附属医院住院治疗的慢性心力衰竭患者96例(心功能均为Ⅱ^Ⅲ级),按就诊顺序随机分为稳心组和药物组,各48例,药物组用基础药物治疗(地高辛+利尿剂+血管扩张药+β受体阻断剂),稳心组在药物治疗基础上加用稳心颗粒,治疗6周后对比两组患者治疗前、治疗后心律失常的情况,并使用汉密尔顿抑郁量表(HAMD)与焦虑自评量表(SAS)评分比较患者焦虑、抑郁症状的改善情况,用SPSS 13.0统计学软件进行数据分析。结果稳心组患者的评分降低较药物组组更显著[HAMD:(8.6±2.6)vs(12.4±4.2);SAS:(37.6±5.9)vs(43.7±6.0)],两组治疗前HAMD、SAS评分比较差异无统计学意义(P>0.05),治疗6周后,HAMD、SAS评分显著低于治疗前(P<0.05);稳心组患者治疗心律失常的总有效率显著高于药物组[95.83%(46/48)vs 35.42%(17/48)](P<0.05)。结论稳心颗粒在辅助治疗慢性心力衰竭患者心律失常的同时能够改善患者焦虑、抑郁症状,治疗作用安全、有效,无明显不良反应。     

稳心颗粒联合丁螺环酮治疗伴有ST-T改变的心脏神经症患者的疗效观察

目的 观察稳心颗粒联合丁螺环酮治疗伴有ST-T改变的心脏神经症的疗效.方法 收集明确诊断为心脏神经症的患者90例,采用随机分组法分为安慰剂组、稳心颗粒组、联合组(稳心颗粒联合丁螺环酮),每组均30例.观察服药4周末和8周末,3组患者的汉密尔顿焦虑量表(HAMA-14)和汉密尔顿抑郁量表(HAMD-24)的得分,以及稳心颗粒联合丁螺环酮治疗12个月后的患者SF-36量表得分和ST-T改善情况.结果 经治疗4周后联合组、稳心颗粒组和安慰剂组的HAMA-14和HAMD-24得分明显低于治疗前(P<0.05);但第8周末比较显示,联合组HAMA-14和HAMD-24得分显著低于稳心颗粒组与安慰剂组,组间差异有统计学意义(P<0.05).3组患者随访12个月后的SF-36得分显示联合组患者的得分明显高于治疗前及其他两组(P<0.05).联合组患者随访结果显示第8周末和第12月末的ST-T改善有效率均显著高于治疗前及其他两组(P<0.05).结论 稳心颗粒联合丁螺环酮治疗心脏神经症显著改善患者的焦虑及抑郁情绪,长期治疗能明显提高患者的生活质量并改善ST-T改变的躯体症状.     

黛力新治疗心脏神经官能症疗效分析

目的观察黛力新治疗心脏神经官能症的疗效。方法将心脏神经官能症患者随机分为常规治疗（对照组）42例和黛力新＋常规治疗（治疗组）42例。治疗组在常规药物治疗的基础上加服黛力新10.5mg,2次/d,共8周;对照组在常规药物治疗的基础上加维生素B6治疗。在治疗前后分别以汉密尔顿抑郁量表（HAMD）评价抑郁严重度,并作为主要疗效指标,采用焦虑量表（HAMA）评价伴发焦虑程度。结果治疗组抑郁量表和焦虑量表评分显著下降,症状明显改善（P〈0.05）。结论常规药物联合黛力新治疗可明显改善心脏神经官能症患者的抑郁症状。     

稳心颗粒对心脏介入患者心理应激的干预研究

目的探讨心脏介入患者的心理应激特点及稳心颗粒对焦虑评分的干预效果。方法对126例有心脏介入指征的患者采用改进的焦虑量表（SAS）进行术前评分,随机分为3组,对照组,心理干预＋稳心颗粒组,心理干预＋坦度螺酮组,对照组只给予心理干预。比较各组患者术后SAS评分情况。结果有心脏介入适应证的患者均不同程度地存在焦虑、抑郁状况等状况,经干预后患者焦虑、抑郁状况明显改善,与对照组比较差异均有极显著性差异（P〈0.01）,稳心颗粒组患者焦虑、抑郁状况明显改善与坦度螺酮组比较差异有统计学意义（P〈0.05）。结论稳心颗粒能明显缓解心脏介入治疗患者围手术期的焦虑、抑郁情绪。     

盐酸帕罗西汀联合胃苏颗粒和莫沙必利对老年非糜烂胃食管反流病伴焦虑抑郁患者的疗效研究

目的:探讨盐酸帕罗西汀联合胃苏颗粒和莫沙必利治疗老年非糜烂性胃食管反流病伴焦虑抑郁患者的疗效和安全性。方法:选择56例非糜烂性胃食管反流病伴焦虑抑郁患者,随机均分为治疗组和对照组。其中对照组28例,予以胃苏颗粒5 g/次,3次/d;枸橼酸莫沙必利片5 mg/次,3次/d;治疗组28例,在对照组的基础上加用盐酸帕罗西汀20 mg/次,1次/d。两组疗程均为4周。比较两组患者治疗第1天及治疗4周后反流性疾病诊断问卷(RDQ量表)评分、Zung焦虑自评量表(SAS)评分和Zung抑郁自评量表(SDS)评分,并比较两组患者临床有效率和不良反应发生情况。结果:治疗4周后,两组患者RDQ量表评分、SAS评分、SDS评分均明显低于治疗第1天,且观察组均明显低于对照组,差异均有统计学意义(P<0.05)。治疗后两组症状如反酸、烧心、胸痛等症状均有明显改善,治疗组总有效率(85.71%)高于对照组总有效率(67.86%)(P<0.05)。药物不良反应发生率比较差异无统计学意义(P>0.05)。结论:盐酸帕罗西汀联合胃苏颗粒和莫沙必利为治疗老年非糜烂性胃食管反流病伴焦虑抑郁患者安全、有效的药物。     

稳心颗粒联合倍他乐克治疗室性早搏96例观察

目的:评价稳心颗粒联合倍他乐克治疗室性早搏的临床效果。方法:186例室性早搏患者,分别采用稳心颗粒联合倍他乐克片和单独稳心颗粒片,维持治疗1年,比较两组室性早搏控制情况,致心律失常作用,发生心血管事件情况前后比较。结果:稳心颗粒联合倍他乐克治疗较单独稳心颗粒治疗对室性早搏控制和心血管事件发生率下降差异有统计学意义,而两组致心律失常作用差异无统计学意义。结论:稳心颗粒联合倍他乐克治疗对控制室性早搏效果和减少心血管事件发生方面明显优于单独使用稳心颗粒,适应证、禁忌证易于掌握,安全范围较大,利于在基层医院使用。     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…